Shaanxi Panlong Pharmaceutical Group Co., Ltd. (SHE:002864)
China flag China · Delayed Price · Currency is CNY
22.08
-0.90 (-3.92%)
Nov 13, 2026, 3:04 PM CST

SHE:002864 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Operating Revenue
915.511,139971.45978.2971.04883.76
Other Revenue
1.881.882.412.633.263.73
917.381,141973.86980.83974.29887.48
Revenue Growth
-16.48%17.15%-0.71%0.67%9.78%32.40%
Cost of Revenue
412.57549.24381.74413.74408.25370.36
Gross Profit
504.82591.62592.12567.09566.04517.12
Selling, General & Admin
361.23416.56436.86418.79416.11386.15
Research & Development
41.3353.1137.5420.2618.2314.03
Other Operating Expenses
8.711.169.3510.6110.239.29
Operating Expenses
427.89504.81485.59453.98452.94414.07
Operating Income
76.9286.81106.53113.11113.1103.05
Interest Expense
-0.58-2.18-1.56-6.11-13.92-3.49
Interest & Investment Income
0.2114.5525.5822.0617.1811.78
Other Non Operating Income (Expenses)
-0.25-0.58-0.220.312.55-5.27
EBT Excluding Unusual Items
76.1298.6130.32129.37118.91106.06
Gain (Loss) on Sale of Investments
0.04-0.13--1.56-0.11-
Gain (Loss) on Sale of Assets
-0.260.13-0.010.17--
Asset Writedown
-0.07-0.01-0.18-0.81-0.08-0
Other Unusual Items
8.2110.376.822.080.462.97
Pretax Income
84.04108.95136.95129.25119.18109.03
Income Tax Expense
21.1812.9317.0317.716.0314.47
Earnings From Continuing Operations
62.8696.02119.92111.55103.1594.56
Minority Interest in Earnings
0.160.260.35-1.11-1.98-1.39
Net Income
63.0296.28120.27110.43101.1693.17
Net Income to Common
63.0296.28120.27110.43101.1693.17
Net Income Growth
-47.70%-19.95%8.91%9.16%8.58%17.77%
Shares Outstanding (Basic)
137136136125111111
Shares Outstanding (Diluted)
137136136127112111
Shares Change
0.51%0.06%7.01%13.03%1.16%-0.60%
EPS (Basic)
0.460.710.880.880.910.84
EPS (Diluted)
0.460.710.880.870.900.84
EPS Growth
-47.97%-20.00%1.77%-3.42%7.33%18.48%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
188.520.674.5441.5369.5335.36
Free Cash Flow Per Share
1.380.150.550.330.620.32
Dividend Per Share
0.1920.2690.1920.1690.1540.139
Dividend Growth
-28.57%39.99%13.65%10.01%11.05%20.02%
Gross Margin
55.03%51.86%60.80%57.82%58.10%58.27%
Operating Margin
8.38%7.61%10.94%11.53%11.61%11.61%
Profit Margin
6.87%8.44%12.35%11.26%10.38%10.50%
Free Cash Flow Margin
20.55%1.81%7.65%4.23%7.14%3.98%
EBITDA
116.14123.15139.04142.92130.16117.8
EBITDA Margin
12.66%10.79%14.28%14.57%13.36%13.27%
D&A For EBITDA
39.2136.3432.5129.8117.0714.74
EBIT
76.9286.81106.53113.11113.1103.05
EBIT Margin
8.38%7.61%10.94%11.53%11.61%11.61%
Effective Tax Rate
25.20%11.87%12.43%13.70%13.45%13.27%
Revenue as Reported
299.421,141973.86980.83974.29887.48
Advertising Expenses
-1.35.041.091.763.68